logo
Share SHARE
FONT-SIZE Plus   Neg

Curis Presents Data On PI3K And HDAC Inhibitor CUDC-907

Curis Inc. (CRIS) announced the presentation of data in a poster session at the American Association for Cancer Research or AACR Annual Meeting 2012 in Chicago, Illinois.

The poster presentation, titled "Antitumor Activity of CUDC-907, a Dual PI3K and HDAC Inhibitor in Hematological Cancer Models", was presented by Rudi Bao, M.D., Ph.D., Curis' Senior Director of Oncology.

The company noted that the poster presentation focused on CUDC-907's biologic activity in cell culture and animal models of various hematological cancers, with a particular focus on multiple myeloma and B-cell lymphoma. In in vitro and in vivo testing, CUDC-907 outperformed a first-in-class HDAC inhibitor as well as an investigational pan-PI3K (Class I) inhibitor given as a single agent or in a combination of both agents.

CUDC-907 also demonstrated enhanced antitumor activity in animal models of B-cell lymphoma and multiple myeloma when co-administered with standard of care agents used in the treatment of patients with these malignancies.

Furthermore, this poster showed that many commonly used in vivo models of B-cell lymphoma and multiple myeloma expressed various PI3K Class I isoforms, suggesting that a pan-PI3K inhibitor such as CUDC-907 may be of greater benefit in many cases than a PI3K inhibitor that is focused narrowly on one PI3K isoform.

The company stated that CUDC-907 showed greater biologic activity than a delta-specific investigational inhibitor in a number of hematological cancer cells in vitro, and showed greater growth-inhibitory activity in an animal model of non-Hodgkin's Lymphoma.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Best Inc., a 23.4 percent owned by e-commerce major Alibaba Group, filed for Initial Public Offering in the U.S. According to the filing, Best expects to offer $750 million american depository shares. We urge Investors to take advantage of the weakness in the shares of Applied Optoelectronics, Inc. (AAOI), as we believe the stock has at least 15% upside from current levels. The stock is down along with many of the stocks in the Fiber optical component universe with an exposure to China. Nestle SA's shares were gaining around 4 percent in Zurich trading after billionaire activist investor Daniel Loeb's hedge fund Third Point LLC bought a $3.5 billion stake in the Swiss food giant. The acquisition of about 1.25% stake in Nestle would put pressure on the company to find ways to accelerate growth.
comments powered by Disqus
Follow RTT